GENELUX CORP
GNLXNASDAQTrading Snapshot
- Day Range
- $2.42 – $2.49
- 52-Week Range
- $2.29 – $8.54
- Volume
- $2.13B
- Avg Volume
- $2.08B
- Shares Outstanding
- 44.8M
- Next Earnings
- Nov 13, 2026
Fundamentals Snapshot
- Annual Revenue
- $8,000
- Last Q Revenue
- $1,974
- P/E Ratio
- -2.8
- P/S Ratio
- 13844.5x
- EPS (TTM)
- $-0.75
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +18.2%
Why Investors Own GNLX
- ✓High-growth profile — revenue up +6.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 65% gross margin and 27% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
GENELUX CORP
GNLX
StockOtter · stockotter.spaceAbout GENELUX CORP
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer and non-small cell lung cancer. The company is also advancing V2ACT Immunotherapy for pancreatic cancer, alongside V-VET1 for the treatment of both hematologic and solid cancers. Founded in 2001, Genelux maintains its headquarters in Westlake Village, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Genelux Announces Publication of a Deep and Durable Response in a Platinum-relapsed Small Cell Lung Cancer Patient Following Systemically Delivered Olvi-Vec-Primed Immunochemotherapy
-- A platinum-relapsed SCLC patient achieved 16.7 months progression-free survival following Olvi-Vec and platinum rechallenge, exceeding the PFS achieved following platinum-based first-line therapy -- -- This patient al
Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates
-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Olvi-Vec systemic development programs continue to advance, with additional dose-escalation updates an
Genelux (GNLX) Projected to Post Quarterly Earnings on Thursday
Genelux (NASDAQ: GNLX - Get Free Report) is expected to post its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.20) per share for the quarter. Par
Genelux Announces Publication of Translational Analysis Supporting Immune Activation and Chemotherapy Sensitization with Olvi‑Vec in Ovarian Cancer
- Findings provide mechanistic support for previously reported clinical outcomes of clinical reversal of platinum resistance/refractoriness from Phase 2 VIRO-15 trial -